期刊论文详细信息
Infectious Diseases and Therapy
Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”
Maarten Postma1  Taj Jadavji2  Francois Peloquin3  Marie-Claude Breton3  Raymond Farkouh4  Matt Wasserman4  Heather L. Sings4  Cheryl McDade5  Stephanie R. Earnshaw5  Michele R. Wilson5 
[1] Department of Pharmacy, University of Groningen;Departments of Pediatrics, Microbiology, Immunology, and Infectious Diseases, Faculty of Medicine, Cumming School of Medicine, University of Calgary;Pfizer Canada Inc.;Pfizer Inc.;RTI Health Solutions;
关键词: Cost-effectiveness;    Health economics;    Pneumococcal disease;    Vaccination;   
DOI  :  10.1007/s40121-018-0221-2
来源: DOAJ
【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次